Title : Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.

Pub. Date : 2014 Jun

PMID : 23821376






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. Oxaliplatin tumor protein p53 Homo sapiens
2 Patients with KRAS/NRAS, BRAF and TP53 wild-type tumours could derive the maximal benefits from treatment with cetuximab, oxaliplatin and UFT. Oxaliplatin tumor protein p53 Homo sapiens